Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical (NASDAQ: AMIX) has reported promising longer-term post hoc analysis results from its PoC 1 study evaluating nerve ablation technology for pancreatic cancer pain treatment. The study demonstrated significant pain reduction of 65.6% (mean 5.08 reduction on VAS pain scale) in responding patients.
Key highlights include 100% opioid-free status among responders at 3-month follow-up, and substantial improvements in quality of life metrics: 76.5% improvement in global health, 51.5% improvement in functional ability, and 50.4% improvement in symptom management. Following these positive results, Autonomix has initiated PoC 2 phase to expand into additional visceral cancers, potentially doubling their addressable market.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.
CEO Brad Hauser will deliver a presentation at the conference, which takes place September 8-10, 2025 in New York. Management will also conduct one-on-one meetings with qualified investors. The presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET and will remain accessible for 90 days on the company's website.
Autonomix Medical (NASDAQ: AMIX) has been granted European Patent No. 3,697,298 for its medical device technology focused on capturing and processing physiological signals. The patent strengthens the company's intellectual property portfolio, which now includes 80 issued patents and 40 pending applications.
The patented technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with enhanced sensitivity. The system includes distributed signal acquisition modules for neural mapping procedures, with capabilities spanning coronary artery/vagal nerve mapping, renal mapping, and various other applications in robotic prosthetics and neurotherapy.
Autonomix Medical (NASDAQ:AMIX), a medical device company specializing in precision nerve-targeted treatments, has announced its participation in an upcoming virtual investor webinar. The event will be hosted by Ladenburg Thalmann on Thursday, August 21, 2025, at 1:00 PM ET.
The webinar will feature Brad Hauser, President and CEO of Autonomix, in a discussion moderated by Jeffrey S. Cohen, Managing Director and Director of Equity Research at Ladenburg Thalmann. The event will include a Q&A session, with participants able to pre-submit questions via email.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, will participate in the upcoming Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies.
The virtual presentation will be delivered by Brad Hauser, President and CEO, on Thursday, August 21, 2025, at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
Autonomix Medical (NASDAQ: AMIX) has completed the final design review of its groundbreaking intravascular nerve sensing catheter, marking a significant milestone toward U.S. clinical trials. The device, featuring a proprietary microchip-based sensing antenna array, is the first of its kind capable of detecting and differentiating nerve signals in real-time from within blood vessels.
The technology enables a novel "sense, treat and verify" approach, allowing physicians to detect nerve activity, guide energy delivery precisely, and confirm treatment efficacy during procedures. The company is preparing to submit an Investigational Device Exemption (IDE) to commence clinical trials, initially focusing on treating pancreatic cancer pain, with potential applications across multiple therapeutic areas including cardiology, pain management, and pulmonary disorders.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the conference, CEO Brad Hauser shared insights about his career journey, his commitment to Autonomix, and his enthusiasm for the company's innovative technology. The presentation is now available for viewing on both the Virtual Investor website and the Events page in the Investors section of autonomix.com.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has secured $2.5 million in gross proceeds through warrant exercises. The company entered agreements with certain warrant holders to exercise warrants for 1,477,596 shares at a reduced price of $1.723 per share.
In exchange for the immediate exercise, Autonomix will issue new unregistered warrants for an equivalent number of shares, exercisable at $1.723 per share with a five-and-a-half-year term. Some holders opted to prepay $1.722 of the exercise price, receiving amended warrants with a $0.001 exercise price. The transaction is expected to close around July 23, 2025.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,295,646 for its "Smart Torquer" device, strengthening its intellectual property portfolio in nerve-sensing and modulation technology. The patent covers a device designed to enhance the manipulation of intravascular devices during minimally invasive procedures while enabling data communication.
The company's technology platform features a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. With over 80 issued patents and 40 pending applications, Autonomix is positioning itself in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released a new CEO Corner segment featuring CEO Brad Hauser. The segment, now available on the company's website, discusses details about the company's recently announced planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
